

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**YiChang HEC ChangJiang Pharmaceutical Co., Ltd.**

**宜昌東陽光長江藥業股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 01558)**

## **FURTHER DELAY IN DESPATCH OF CIRCULAR IN RELATION TO CONTINUING CONNECTED TRANSACTIONS**

Reference are made to the announcements of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (the “**Company**”) (i) dated 27 April 2022 (the “**Announcement**”) in relation to, among other things, the Energy Purchase Framework Agreement, the APIs Purchase Agreement, the Packaging and Production Materials Purchase Framework Agreement, the Equipment Purchase and Civil Construction Framework Agreement, the Entrusted Processing Framework Agreement, the Leasing and Other Services Framework Agreement, the APIs and Pharmaceutical Products Sales Framework Agreement and the Entrusted Production and Inspection Services Framework Agreement (the “**Continuing Connected Transactions Agreements**”) (including their respective proposed annual cap); (ii) dated 24 June 2022 in relation to the delay in despatch of the Circular (as defined hereinbelow); and (iii) dated 14 July 2022 (the “**Delay Announcement**”) in relation to further delay in despatch of the Circular (as defined hereinbelow). Capitalised terms used herein shall have the same meaning as those defined in the Announcement and Delay Announcement unless the context otherwise requires.

As disclosed in the Delay Announcement, a circular (the “**Circular**”) containing, among other things, (i) further details of the Continuing Connected Transactions Agreements (including their respective annual cap); (ii) the recommendation of the Independent Board Committee in respect of the Continuing Connected Transactions Agreements (including their respective proposed annual cap); (iii) a letter of advice from the Independent Financial Advisor to the Independent Board Committee and the Independent Shareholder(s) in respect of the Continuing Connected Transactions Agreements (including their respective proposed annual cap); and (iv) other information as required by the Listing Rules was expected to be despatched to the Shareholders on or before 31 July 2022. As additional time is required to finalise certain information to be included in the Circular, it is expected that the despatch date of the Circular will be further postponed to a date on or before 5 August 2022.

On behalf of the Board

**YiChang HEC ChangJiang Pharmaceutical Co., Ltd.**

**TANG Xinfa**

*Chairman*

Hubei, the PRC  
29 July 2022

*As of the date of this announcement, the Board consists of Mr. JIANG Juncai, Mr. WANG Danjin, Mr. CHEN Yangui and Mr. LI Shuang as executive Directors; Mr. TANG Xinfu and Mr. Eddy HUANG as non-executive Directors; and Mr. TANG Jianxin, Mr. ZHAO Dayao, Ms. XIANG Ling and Mr. LI Xuechen as independent non-executive Directors.*